OrbiMed — Full Portfolio

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

BOBenjamin Oakes(Founder & CEO)inJAJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)BLBenjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)BSBrett Staahl, PhD(Co-founder, VP of External Innovation)

BoardVPVijay Pande(Director)in

Co-investorsANAndreessen HorowitzAVAvoro Capital AdvisorsMEMenlo VenturesRARA CapitalAVAvoro Ventures

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

GGreg(Co-founder & Senior Vice President of Discovery Research)MMark(Co-founder & Senior Vice President of Medicinal Chemistry)MMike(President & CEO)CCharlotte(Chief Medical Officer)EElena(Chief Financial Officer)CCaroline(Chief Business Officer)

Co-investorsATAtlas VentureRARA Capital

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)inAAAllison Ambrose(General Counsel)inADAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)AHAdam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsACAccess IndustriesACAccess BiotechnologyBABain Capital Life SciencesDEDecheng CapitalSASamsara BioCapitalTCTCG Crossover+2 more

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)DLDave Lennon(Executive Officer, Director)inDDDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017

Co-investors3B3B Future Health FundALAlly Bridge GroupDEDecheng CapitalVIVivo CapitalAVAvoro Ventures

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)NHNathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

BoardFlorent Gros(Director)

Board seatJSJonathan SilversteinCGCarl Gordon· per SEC Form D

Co-investorsFOForesite CapitalPOPontifax Venture CapitalQUQuan CapitalAMaMoonNONovartis Venture FundPUPureTech Health

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

SCSean Cassidy(Executive Officer)inMLManuel Litchman(Executive Officer, Director)inRTRandy Teel(President and Chief Executive Officer; Director)in

BoardLRLiam Ratcliffe(Director)inTSTim Shannon(Director)in

Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018

Co-investors5A5AM VenturesACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsNENextech InvestRARA Capital+1 more

CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.

BiotechHealthtechLa Jolla, US

KAKenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)MJMichael J. Dunn(Executive Officer)inSBStephen Bardin(Chief Financial Officer)in

Board seatChau Khuong· per SEC Form D

Co-investorsAIAisling CapitalSASanderling VenturesCLClarusCLClarus Lifesciences

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

STSchuetz Thomas(Executive Officer, Director)inEAErrik Anderson(Executive Officer, Director)inTJThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNLNeil Lerner(Senior Vice President, Chief Accounting Officer)in

Board seatStephen SquintoCGCarl Gordon· per SEC Form D

Co-investorsBIBioBritF-F-Prime CapitalFOForesite CapitalVEvenBio PartnersVIVivo CapitalBOBorealis Ventures+1 more

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

JGJames G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Board seatDBDavid Bonita· per SEC Form D

Co-investorsBABay City CapitalNENew Enterprise Associates (NEA)RARA CapitalARArix Bioscience

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.

BiotechHealthtechLexington, US

Jasbir S. Seehra(Executive Officer, Director)inJasbir Seehra(Co-Founder, Chief Executive Officer and Director)in

BoardJulius Knowles(Director)ALAlon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in

Board seatCGCarl Gordon· per SEC Form D

Co-investorsARArkin CapitalFOForesite CapitalPOPontifax Venture Capital

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)inPLPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019

Co-investorsNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsOUOUP (Osage University Partners)

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUGUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSKSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Board seatChau Khuong· per SEC Form D

Co-investorsBABay City CapitalCACanaan PartnersLALAVLILilly Asia VenturesPFPfizer Venture InvestmentsQUQuan Capital+4 more

Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors.

BiotechHealthtechNewark, US

Krishna Vaddi(Executive Officer, Director)

BoardPaul Friedman(Director of Issuer)

Board seatDBDavid Bonita· per SEC Form D

Co-investorsTHThe Innovation Space

SI-BONE develops medical devices for treating sacroiliac (SI) joint dysfunction and chronic low back pain, targeting patients and physicians.

HealthtechMedical DevicesSan Jose, US

Mark Reiley(Director)inJWJeffrey W. Dunn(Executive Officer, Director)Robert E. Johnson(Executive Officer)Dan Murray(Executive Officer)LALaura A. Francis(Chief Executive Officer)

BoardTimothy E. Davis(Director)

Board seatDBDavid Bonita· per SEC Form D · $21M raise · filed Jun 2016

Co-investorsARArboretum VenturesMOMontreux Equity Partners

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

JSJavier Szwarcberg(Executive Officer, Director)inSGSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in

BoardSimpson Camilla(Director)TATiba Aynechi(Director)in

Board seatDCDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023

Co-investorsAIAisling CapitalHEHealthCapRIRiverVest Venture PartnersABAbingworthNONorwest Venture PartnersNONovo Holdings+1 more

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

BCBharatt Chowrira(Executive Officer)inMSMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPMPaul Miller(Executive Officer)inABAoife Brennan(Executive Officer)inTSTodd Shegog(Executive Officer)in

Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017

Co-investorsATAtlas VentureNENew Enterprise Associates (NEA)NSNSG VenturesPFPfizer Venture InvestmentsSOSofinnova VenturesSOSolasta Ventures

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHGHalley Gilbert(Executive Officer)RDRebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFIFidelity InvestmentsFOForesite CapitalGVGV (Google Ventures)MIMITHRILMIMithril Capital ManagementPOPolaris Partners+3 more

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

CRChad Robins(Executive Officer, Director)inHRHarlan Robins(Executive Officer)inKDKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)KPKyle Piskel(Chief Financial Officer)in

Co-investorsDEDecheng CapitalFMFMG CapitalFOForesite CapitalKHKhosla Ventures

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

MBMartin Babler(President, Chief Executive Officer and Chairman of the Board)inMBMark Bradley(Chief Development Officer)inKBKolbot By(SVP, Head of Technical Operations)inJDJack Danilkowicz(Chief Commercial Officer)inJDJörn Drappa(Chief Medical Officer)inDMDavid M Goldstein(Chief Scientific Officer)in

Co-investorsFOForesite CapitalNENextech InvestSASamsara BioCapitalSRSR One Capital ManagementVEvenBio PartnersWEWestlake Village BioPartners+1 more

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)EDElisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsADAdvent Life SciencesCHChiesi VenturesDRDroia VenturesFOForesite CapitalJAJazzya InvestmentsMEMedicxi+4 more

RECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts.

BiotechHealthtechMedical DevicesMelbourne, US

Fiona WoodDADale A Sander(Executive Officer)inCVCary Vance(Executive Chairman & Interim Chief Executive Officer)in

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

KFKristen Fortney, PhD(Co-Founder, CEO)EMEric Morgen, MD(Co-Founder, COO)KFKristen Fortney(Executive Officer, Director)inEMEric Morgen(Director)inDGDov Goldstein(Executive Officer)in

BoardPEPatrick Enright(Director)in

Co-investorsANAndreessen HorowitzELElad GilFEFelicis VenturesIAIA Seed VenturesLOLongitude CapitalPEPear VC+5 more

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.

AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardware

Jonathan Solomon(Chief Executive Officer)inMBMerav Bassan(Chief Development Officer)inMWMarina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)

Co-investorsAMAMR Action FundBABaruch Future VenturesNSNSG Ventures8V8VC

Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.

AI & Machine LearningBiotechHealthtech

DDDavid Dean Halbert(Chairman, Founder and CEO)

Co-investorsCOCoatue ManagementSISilver Lake PartnersSISixth StreetBRBraidwellMIMillennium Management

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)SFStephen F. Betz(Executive Officer)inSBStephen Betz(Chief Scientific Officer)inRSR. Scott Struthers(President, Chief Executive Officer and Director)inTSTobin Schilke(Chief Financial Officer)inIKIsabel Kalofonos(Chief Commercial Officer)in

Co-investors5A5AM VenturesFOForesite CapitalRARA CapitalVIVivo Capital

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

MKMary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)JMJennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNANadim Ahmed(President and Chief Executive Officer)in

Co-investorsFOForesite CapitalNENextech InvestBIBiotechnology Value Fund

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtechSouth San Francisco, US

Sean McCarthy(Executive Officer, Director)inSASean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWCWayne Chu(Chief Medical Officer)RLRachael Lester(SVP, Chief Business Officer)in

Co-investorsCACanaan PartnersLOLongitude CapitalPFPfizer Venture InvestmentsTHThird Rock Ventures

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

GWGarrett Winslow(Executive Officer)inLFLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsACAccess BiotechnologyBABAM ElevateBABay City CapitalCOCommodore CapitalEIEIR VenturesFOForbion+6 more

Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits.

BiotechDigital HealthHealthtechMental HealthWellness & FitnessNew York, US

Oren Fuerst, PhD(Director)ERErez Raphael(Chief Executive Officer)inZBZvi Ben David(Chief Financial Officer, Treasurer, and Secretary)inSNSteven Nelson(Chief Commercial Officer)inGLGadi Levin(Executive Officer, Director)in

BoardAdam K. Stern(Director)

Co-investorsAGAgate Medical Investments LPPIPitango

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesFOForesite CapitalFRFrazier Life Sciences5A5AM Ventures+6 more

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)inARAlan Russell(Director)inBEBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)

BoardPTPeter Thompson(Director)inJRJonathan Root(Director)in

Co-investorsBOBoulder VenturesFOForesite CapitalUSUS Venture PartnersDEDeerfield Management CompanyNONovo Holdings

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

FEFuad El-Hibri(Director, Executive Officer)inRGRobert G Kramer(Executive Officer)inKatherine Strei(Executive Officer)ARAdam R Havey(Executive Officer)inDJDaniel J Abdun-Nabi(Executive Officer, Director)inJCJoseph C. Papa(President, CEO and Director)

Co-investorsADAdvent Life Sciences

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5A5AM VenturesPFPfizer Venture InvestmentsRORoche Venture FundARARCH Venture PartnersBABay City CapitalNENew Enterprise Associates (NEA)+1 more

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

WLWill Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSBSara Bonstein(Chief Financial Officer)inRARoger Adsett(Chief Operating Officer)MFMartina Flammer(Chief Medical Officer)inSNS. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBEBessemer Venture PartnersF-F-Prime CapitalFOForesite CapitalPRProspect Venture PartnersNVNVIDIA

InspireMD develops and commercializes medical devices for vascular intervention, including carotid stent systems and embolic protection systems sold through direct sales in the United States and via distributors in international markets.

BiotechHealthtechMiami, US

Patrick Verta(Executive Officer)inPLPete Ligotti(Executive Officer)inMike Lawless(Chief Financial Officer)SGShane Gleason(Executive Officer)inMSMarvin Slosman(President and Chief Executive Officer)inATAndrea Tommasoli(Chief Operating Officer)

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAGage1ATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalFIFidelity Investments

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

MEMarc Elia(Founder)in

Co-investorsBABain Capital Life SciencesFOForesite CapitalMRMRL Ventures FundPRPremji InvestGVGV (Google Ventures)MIMITHRIL+3 more

NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.

Digital HealthHardwareHealthtechMedical DevicesMountain View, US

RKRebecca Kuhn(Executive Officer)inFFFrank Fischer(Executive Officer, Director)JBJoel Becker(President, Chief Executive Officer and Director)inVince Burgess(Director)inRRRenee Ryan(Director)inRay Larkin(Director)

Co-investorsACAccelmed PartnersNENew Enterprise Associates (NEA)

The Oncology Institute operates a national network of 65 affiliated physician clinics and contracts with independently-owned oncology and hematology practices to deliver outpatient cancer care through fee-for-service arrangements and value-based contracts that shift financial risk to the company.

HealthtechCerritos, US

Robert Carter(Executive Officer)Jeremy Castle(Executive Officer)Daniel Virnich(Executive Officer, Director)YPYale Podnos(Executive Officer)inBrad Hively(Director)MSMihir Shah(Executive Officer)in

Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.

BiotechNewtown, US

Ramesh Kumar, Ph.D(Executive Officer, Director)E. Premkumar Reddy(Director)Manoj Maniar(Executive Officer)inThomas McKearn(Executive Officer)ABAjay Bansal(Executive Officer)inSFSteven Fruchtman(Executive Officer)in

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsECEcoR1 CapitalNENew Enterprise Associates (NEA)NENextech InvestTATaiho Ventures, LLCTHThe Column Group

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

WCWilliam Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

BoardPHPatrick Heron(Director)inCGCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFRFrazier Life SciencesACAccess BiotechnologyFRFrazier Healthcare PartnersNENew Leaf Venture PartnersVEVersant VenturesVIVivo Capital

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEOEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBIBioAdvanceBABAM ElevateBRBraidwellCOCommodore CapitalJAJanus Henderson InvestorsRARA Capital+2 more

Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.

BiotechHealthtechAustin, US

JHJosiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)

BoardWalter Loewenbaum(Director)

Co-investorsECEcoR1 CapitalHAHatteras Venture PartnersREREDMILET.T. Rowe Price

Sonendo is a medical technology company that develops and manufactures the GentleWave System, a technology platform for treating tooth decay by cleaning and disinfecting the interior spaces of teeth without removing tooth structure.

HardwareHealthtechMedical DevicesLaguna Hills, US

BBBjarne Bergheim(Executive Officer, Director)inJMJohn McGaugh(Executive Officer)inJBJohn Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)Roy T. Chen(Chief Talent Officer)Chris Guo(Interim Chief Financial Officer)in

Co-investorsESEssex Woodlands Healthcare PartnersFJFjord VenturesGEGeneral AtlanticMEMeritech Capital PartnersPUPura Vida InvestmentsWEWelsh, Carson, Anderson & Stowe

Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.

BiotechMalvern, US

Antony Koblish(Founder)inFrancis Conway(Executive Officer)MPMaarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)

BoardKRKevin Rakin(Director)inAshley Freidman(Director)

Co-investorsCHCheckmate Capital Group LLCESEssex Woodlands Healthcare PartnersHIHighCape CapitalSISignet Healthcare Partners131315 CapitalRTRTW Investments L.P.

Traws Pharma is a pharmaceutical company developing therapeutics, with a leadership focus spanning oncology, infectious disease, and medical science areas.

BiotechHealthtech

IDIain Dukes(Chief Executive Officer)inCharles Parker(Chief Financial Officer)C. David Pauza, PhD(Chief Science Officer)Robert R. Redfield, MD(Chief Medical Officer)Victor Moyo, MD(CMO Oncology)Nikolay Savchuk, PhD(Chief Operating Officer)

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

RWRobert WeinbergRICHARD ALDRICH(Director)ACAMY C. CAVERS(Executive Officer)inCCCATHY CAREW(Executive Officer)inJPJONATHAN PACHTER(Executive Officer)inRGROB GAGNON(Executive Officer)in

Co-investorsBEBessemer Venture PartnersCACardinal PartnersFOForesite CapitalLILightstone VenturesLOLongwood FundOBOberland Capital

Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma.

BiotechHealthtechMedical DevicesWest Chester, US

NRNoah Rosenberg(Executive Officer)inJohn Kirby(Executive Officer)Matthew Davidson(Executive Officer, Director)

BoardJRJayson Rieger(Executive Officer, Director)inPBPaul B. Manning(Director)inDZDavid Zawitz(Executive Officer)

Co-investorsPBPBM Capital

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.

BiotechHealthtechMedical DevicesChanhassen, US

Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)

BoardIEImran Eba(Executive Officer)in

Board seatKlaus Veitinger· per SEC Form D

Co-investorsHEHealthQuest CapitalSASamsara BioCapitalSVSV Health InvestorsACAction Potential Venture Capital Ltd.

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.

BiotechHealthtechMedical DevicesSan Francisco, US

SGSevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)in

BoardChristy Shaffer(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)in

Board seatChau Khuong· per SEC Form D

Co-investorsACAccess BiotechnologyCACatalio Capital Management, LPHAHatteras Venture PartnersLALAVLILilly Asia VenturesHAHatteras

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical Devices

ZLZhen Li(Co-founder, President & CEO)inRZRui Zhu(Founding Member & Chief Technology Officer)RARob Ackles(Chief People Officer)inRFRyan Fisk(Chief Financial Officer & Chief Business Officer)inRARobert A. MacLeod(Chief Scientific Officer)inCCChristopher Claeboe(Senior Vice President of Operations)in

Co-investorsBABain Capital Life SciencesLILilly Asia VenturesSRSR One Capital ManagementT.T. Rowe PriceTCTCG CrossoverVIVivo Capital

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.

BiotechHealthtechMedical DevicesRaleigh, US

Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)JFJohn Fahy(Director)in

BoardCSChristy Shaffer(Director)inRishi Gupta(Director)inTSTim Shannon(Director)in

Co-investorsHAHatteras Venture PartnersCACanaan PartnersPAPappas Capital

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

TBThomas Baumert(Founder)inMPMark Pruzanski(Chief Executive Officer)inLMLuigi Manenti(Chief Medical Officer)inJFJon Freve(Chief Financial Officer)inBYBryan Yoon(General Counsel and Chief Administrative Officer)inAVAditya Venugopal(Chief Business Officer)in

Co-investorsAVAvego BioScience CapitalBIBioMedPartnersFRFrazier Life SciencesJEJeito CapitalLOLongitude CapitalNONovo Holdings+5 more

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical Devices

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDMDamien McDevitt(President and Chief Executive Officer)in

Co-investorsARARCH Venture PartnersLILifeforce CapitalDODomain AssociatesEDEDB InvestmentsSESection 32FRFrazier Life Sciences+4 more

Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery.

AI & Machine LearningBiotechHealthtech

MMMegan McGill(Chief Executive Officer)inIDIain Dukes(Chief Business Officer / Chairman of the Board)inNSNikolay Savchuk(Chief Operating Officer)TDTien Dam(Chief Medical Officer)in

Co-investorsNENew Enterprise Associates (NEA)BGBGVTOTorrey Pines Investment

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

CDClarissa Desjardins(Founder)in

Co-investorsALAlexandriaDIDIMENSIONBDBDC Thrive Venture Fund for WomenLULumira Ventures

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

PJPhilip JaniakinMOMarie-Laure OzouxinRORégis OlivierinFrancesca C. LawsonMark KowalaEJEleonore Jouannyin

Co-investorsFOFountain Healthcare PartnersJEJeito CapitalKUKurma PartnersV-V-Bio VenturesOMOmnes CapitalINInvivo Capital Partners+1 more

Entero Healthcare Solutions is a healthcare products distribution company operating in India, connecting pharmaceutical manufacturers with pharmacies and healthcare providers.

HealthtechLogistics & Supply Chain

Prem Sethi(Promoter, Whole-time Director & COO)inPAPrabhat Agrawal(Promoter, Managing Director & CEO)in

Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.

BiotechHealthtechMedical DevicesLyon, FR

JVJacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)inBDBenoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)JGJean-Jacques Garaud(Co-founder)in

Co-investorsANAndera PartnersSOSofinnova PartnersBPBpifrance

Forward Therapeutics develops oral small-molecule medicines targeting inflammation-driven diseases, using a structure-based, data-driven discovery engine to design drugs against validated pathways.

AI & Machine LearningBiotech

Co-investorsCUCurie.Bio

Frontera Therapeutics is a biotechnology company engaged in therapeutic research and development, spanning translational medicine, clinical operations, and manufacturing.

BiotechDeep TechHealthtechBoston, US

Xinyan Li(CEO)

Co-investorsBOBoyu CapitalCRCreacion VenturesHOHongShan Capital Group

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

JBJane Buckner(Scientific Co-founder (President, Benaroya Research Institute))CPChandra Patel(Co-founder & SVP, Research and Development Operations)inDRDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)ASAndy Scharenberg(Scientific Co-founder, SAB Chair)AWAndy Walker(President and CEO)inTWTom Wickham(Chief Scientific Officer)

Co-investorsNONovartis Venture FundJDJDRF T1D FundRARA Capital

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

WWWilliam Wei Caoin

Co-investorsLALAVLILilly Asia VenturesEXExome Asset ManagementJAJanus Henderson InvestorsPIPivotal Life SciencesRARA Capital+2 more

i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.

BiotechDeep TechHealthtechSan Diego, US

Co-investorsTOTorrey Pines InvestmentBIBioGeneration VenturesBGBGV

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

JMJames M. Wilson(Scientific Founder)JTJoseph Truitt(CEO & Board Member)inPFPaul Firuta(COO)inAMAlex Monteith(Chief Business Officer)David Garrett(CFO)inGMGabriel M. Cohn(Chief Medical Officer)in

Co-investorsLYLYFE CapitalVEVersant Ventures

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong

AZAlex Zavoronkov(Director)AZAlex Zhavoronkov(Founder & CEO)inAAAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

BoardNisa Leung(Director)Lennart Lee(Director)

Co-investorsLILilly Asia VenturesQIQiming Venture PartnersWAWarburg PincusBABaidu VenturesEIEight Roads VenturesLALake Bleu Capital+9 more

Lattice Medtech distributes medical devices and offers strategic manufacturing and full-service distribution partnerships for medical device companies.

HealthtechLogistics & Supply ChainMedical Devices

Rahul Garg(CEO & Founder)Rahul Bagaria(CFO)

MDClone provides a healthcare data platform that uses synthetic data to support clinical research and care-improvement initiatives, used by health systems such as Intermountain for programs targeting chronic conditions like kidney disease, diabetes, and cardiovascular disease.

AI & Machine LearningData & InfrastructureDigital HealthHealthtech

ZOZiv Ofek(Co-Founder and President)inBLBruno Lempernesse(Chief Executive Officer)inAaron Galaznik(Chief Medical Officer)inAOAlmog Ohayon(Chief Product and Technology Officer)in

Co-investorsAMaMoonLILightspeed Venture PartnersWAWarburg PincusDEDeclaration PartnersVIViola Ventures

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsADAdjuvant CapitalINIndustrifondenPUPureos BioventuresSASanofi VenturesSUSunstone CapitalEQEQT Life Sciences+2 more

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)

Co-investorsCACatalio Capital Management, LPF-F-Prime CapitalSOSofinnova VenturesINInsight PartnersNVNVIDIA

QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.

AI & Machine LearningBiotechDeep Tech

Co-investorsSASanofi VenturesCRCreacion VenturesLILilly Asia Ventures

Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.

BiotechHealthtechLongevityMedical DevicesSan Diego, US

Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)

Co-investorsDEDelos CapitalCRCreacion Ventures

Uquifa is a supplier of active pharmaceutical ingredients and related products for the human and animal health markets, emphasizing quality standards and regulatory compliance.

Advanced ManufacturingBiotechHealthtechNew MaterialsBarcelona, ES

SGSaurabh Gurnurkar(Managing Director & CEO, Uquifa Group)inPilar Valle(Chief Financial Officer)inAPAlfred Pascual(Corporate Manufacturing Operations Director)inPéter Ács(General Manager & Chief Operating Officer – Soneas Chemicals Ltd.)

Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.

AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US

HNHaim Neerman(Co-founder)inTJTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJWJeffrey Weisberg(Chief Financial Officer)inYRYaron Rachmany(Operations, R&D, IT (executive))inCSChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in

Co-investors2020/20 HealthCare Partners LLCBOBosch VenturesNENew Era Capital PartnersPEPeregrine VenturesPIPitangoQUQuark Venture Inc.+2 more

Whale Imaging is a medical imaging company.

HardwareHealthtechMedical DevicesBoston, US

Sean Z.(Founder)in

Co-investorsSESequoia Capital

HealthtechCarlsbad, US

CSChristoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVBVince Burgess(Director)inJohn Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Board seatDBDavid Bonita· per SEC Form D

Co-investorsADAdvent Life SciencesDEDeerfield Management CompanyFOFormation GroupGEGE VenturesINIndex Ventures

Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

DDDaniel Diniz De Carvalho(Executive Officer, Promoter)SBScott Bratman(Executive Officer, Director)inAHAnne-Renee Hartman(Founder)inAWAlan Williams(Executive Officer)inLALisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in

Board seatDBDavid Bonita· per SEC Form D

Co-investorsDEDecheng CapitalF-F-Prime CapitalDEDeerfield Management CompanyMEMenlo Ventures

BiotechCincinnati, US

RSRobert Shalwitz(Executive Officer)JGJoseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)

Board seatChau Khuong· per SEC Form D

Co-investorsCICincyTechSOSofinnova Ventures

Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.

BiotechHealthtechMedical DevicesCambridge, US

PJPaul Jaminet(Executive Officer, Director)in

BoardErrik Anderson(Director)JCJason Camm(Director)inJAJonathan Adams(Director)inFHFabian Hansen(Director)in

Board seatIDIain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025

Co-investorsGRGreen Meadow VenturesK5K5 Global

BiotechSan Francisco, US

MPMatthew Patterson(Executive Officer, Director)in

BoardSteve Squinto(Director)inKPKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)

Board seatJSJonathan Silverstein· per SEC Form D · filed Sep 2015

Co-investorsASAsset Management CompanyRARA CapitalVEvenBio Partners5A5AM VenturesDEDeerfield Management CompanyVEVenrock

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechHealthtechMedical DevicesWatertown, US

RMRichard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)

BoardRoy Amariglio(Director)Nick Olsen(Director)inMichal Silverberg(Director)in

Board seatStephen Squinto· per SEC Form D

Co-investorsDEDeep InsightDEDelos CapitalNONovartis Venture Fund

Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU.

BiotechHealthtechNew York, US

DMDonnie McGrath(CEO & Co-Founder)MDMegan Dow(COO & Co-Founder)TDTania Dimitrova(CFO & Co-Founder)GRGlenn Rosen(Chief Translational Officer & Co-Founder)StJohn Donnie McGrath(Executive Officer, Director)

BoardBo Chen(Director)

Board seatCGCarl Gordon· per SEC Form D

Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.

BiotechHealthtechMedical DevicesWestminster, US

Andrew J. Tofe(Director)inBPBritt Pearson(Executive Officer)inJeff Marx(Executive Officer)inGKGlen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)

Board seatChau KhuongJSJonathan Silverstein· per SEC Form D · $4M raise · filed Feb 2015

Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.

BiotechHealthtechTel Aviv

Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)JQJill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inAAArnon Aharon(Executive Officer)in

Board seatStephen Squinto· per SEC Form D

Co-investorsALAltium Capital

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)inSMSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

BoardMMMarcos Milla(Director)inJLJay Lichter(Director)inTRTighe Reardon(Executive Officer)

Board seatStephen Squinto· per SEC Form D · $15M raise · filed Sep 2025

Co-investorsFRFrazier Life SciencesLILightspeed Venture PartnersSASamsara BioCapitalAVAvalon BioVenturesPAPappas CapitalPFPfizer Venture Investments+1 more

BiotechPennington, US

CDChris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)inDale Ludwig(Mr. Ludwig is the Chief Scientific Officer)inAnuj Goswami(Mr. Goswami is the General Counsel and Secretary)inCPClaudine Prowse(Ms. Prowse is the Chief Financial Officer)inGary Sender(Director)Julie Hambleton(Director)

Board seatChau Khuong· per SEC Form D · $55M raise · filed Dec 2021

Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective.

Digital HealthHealthtechMedical DevicesGolden Valley, US

THTim Herbert(Founder)in

BoardMudit Jain(Director)JEJoyce Erony(Director)inDana Mead(Director)CTCasey Tansey(Director)

Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016

Co-investorsAMAmzak HealthAPAPERTURE Venture PartnersUSUS Venture Partners

Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.

BiotechHealthtechWoburn, US

CDCyril De Colle(Founder)inCDCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JOJAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in

BoardDADAVID ALLISON(Director)in

Board seatKevin KochKlaus Veitinger· per SEC Form D

Co-investors5A5AM VenturesSASamsara BioCapitalVEvenBio PartnersVIVivo CapitalRTRTW Investments L.P.VEvenBio Global Strategic+1 more

Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.

Digital HealthMedical DevicesWellness & FitnessPleasanton, US

SRShri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)

BoardAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in

Board seatChau Khuong· per SEC Form D

Co-investorsANAngelini VenturesBLBlue Venture FundsTRTreo Ventures, LlcZÜZühlke VenturesBRBridge BankSASandbox Clinical Ventures+1 more

BiotechBoston, US

DDDarlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDMDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in

BoardChristina Takke(Director)Steven Prelack(Director)

Board seatChau Khuong· per SEC Form D · $16.5M raise · filed Jun 2016

Co-investorsBIBiotechnology Value FundFRFrazier Life Sciences

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.

BiotechHealthtechMental HealthMilwaukee, US

DBDavid Baker, PhD(Director)DLDaniel Lawton(Executive Officer, Director)TBTom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)

Board seatKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019

Co-investorsAIAisling CapitalF-F-Prime Capital

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBHBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDMDavid Meeker(President and Chief Executive Officer)in

BoardETEdward T. Mathers(Director)inNENeil Exter(Director)in

Board seatJSJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsTHThird Rock Ventures

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.

BiotechHealthtechMedical DevicesPortland, US

RJRobert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)

BoardJRJonathan Root(Director)inNONiall O'Donnell(Director)inZSZach Scheiner(Director)in

Board seatKlaus Veitinger· per SEC Form D

Co-investorsRARA CapitalRIRiverVest Venture PartnersUSUS Venture Partners

BiotechCambridge, US

William C. Shakespeare(Director)in

BoardIDIain Dukes(Executive Officer, Director)inMRMichael Rome(Director)in

Board seatCGCarl Gordon· per SEC Form D

Co-investorsFOForesite CapitalLOLongitude CapitalNENextech InvestNENexTech VenturesPOPontifax Venture CapitalRORock Springs Capital+1 more

Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.

BiotechHealthtechMedical DevicesKingston, US

Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)JCJohn Cerminaro(Executive Officer)inMJMichael J. Cerminaro(Executive Officer, Director)inMarvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)

Board seatDBDavid Bonita· per SEC Form D

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechMedical DevicesWatertown, US

JHJoshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in

BoardKBKristina Burow(Director)inAli Satvat(Director)DSDavid Schenkein(Director)in

Board seatDBDavid Bonita· per SEC Form D

Co-investorsAIAisling CapitalARARCH Venture PartnersCACasdin CapitalFIFidelity InvestmentsGVGV (Google Ventures)RORock Springs Capital+1 more

BiotechSouth San Francisco, US

Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)

BoardSandra Coufal(Director)Robert Alpern(Director)

Board seatKlaus VeitingerDBDavid Bonita· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsLOLongitude CapitalFRFrazier Life SciencesHEHercules Capital, Inc.WEWellington Management

ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.

HardwareHealthtechMedical DevicesOakwood Village, US

JFJames F. Dempsey(Executive Officer, Director)inDavid Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)CAChris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)Gregory M. Ayers(President and Chief Executive Officer of the Issuer.)

Board seatDBDavid Bonita· per SEC Form D · filed Aug 2015

Co-investorsAIAisling CapitalF-F-Prime Capital

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHUHurricane VenturesANAndreessen HorowitzASAscenta CapitalAVAvaana CapitalBOBoxGroupCLClaypond Capital+7 more

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVIVida VenturesHEHealthCapJEJeito CapitalNONovo HoldingsPOPontifax Venture CapitalRARA Capital+2 more

Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.

AI & Machine LearningBiotechDeep TechVermont, US

Co-investorsGRGrandBanks CapitalLALaunchCapitalLULux CapitalMIMithril Capital ManagementPRPremji InvestSVSV Health Investors+1 more

Advanced Enzymes is a company in the enzyme/biotech industry; the page shown is an investor relations section with quarterly financial results, shareholding patterns, and corporate governance reports.

BiotechFoodTechNew Materials

Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.

HealthtechMedical DevicesMountain View, US

MBMatt Brokaw(CEO & President)inDerrick Sung(Executive Officer)inMSMatthew Salkeld(Executive Officer)IRIrina Ridley(Executive Officer)inAndre Cheng(Executive Officer)inFDFred Dinger(Executive Officer, Director)in

Co-investorsLALaunchCapitalQUQuesta CapitalTATargeted Technology FundsALAlly Bridge GroupHOHorizon

Asian Institute of Medical Sciences is a hospital in India providing healthcare services with accreditation from NABH, NABL, and AACI.

Digital HealthHealthtechMedical DevicesFaridabad, IN

AirStrip develops clinical decision support and patient monitoring software, including data-driven and AI predictive analytics tools, for hospitals, health systems, and clinicians.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaSSan Antonio, US

APAlan Portela(Executive Officer, Director)inDr. Naseem(Chief Executive Officer)LSLauren Schiegg(Chief Operating Officer)inHRHari Radhakrishnan(Chief Medical Officer)inSHSken Huang(Chief Financial Officer)inRory(Chief Commercial Officer)

AK Medical is a company providing investor and corporate information, headquartered in Beijing with a principal place of business in Hong Kong.

Advanced ManufacturingHardwareHealthtechMedical DevicesBeijing, CN

Co-investorsDEDecheng Capital

BiotechSeattle, US

Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJPJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)

Co-investorsDEDecheng CapitalFRFrazier Life SciencesBIBiotechnology Value Fund

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)

BoardTSThilo Schroeder(Director)inCGCarl Gordon(Director)inAGArjun Goyal(Director)in

Co-investorsCACanaan PartnersNENextech InvestVIVida VenturesDIDigitalis VenturesNVNVIDIA

Altis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesToronto, CA

FBFelix Baldauf-Lenschen(Founder & CEO)inJohn(CTO)

Co-investorsCRCreative Destruction Lab (CDL)DEDebiopharm Innovation FundFUFusionBEBenchstrength Partners

AnchorDx develops, manufactures, and sells cancer early-screening and diagnostic products based on ctDNA methylation high-throughput sequencing, along with related testing services covering over 70% of high-incidence cancers such as lung, breast, digestive, and urinary cancers.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesGuangzhou, CN

范建兵(Founder)

Co-investorsMAMarathon Venture Partners6 6 Dimensions Capital

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsFRFrazier Life SciencesRARA CapitalFRFrazier

Arcatron designs and sells mobility and assistive products under the Frido brand, including electric and manual wheelchairs, mobility scooters, transfer lifts, walking aids, shower and hygiene aids, and bath mats.

ConsumerE-commerceMedical Devices

Dewaj Baruah(Founder)in

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.

BiotechDeep TechSan Diego, US

JYJin-Quan Yu(Founder)inJin-Quan Yu, Ph.D.(Scientific Founder)BCBen Cravatt Ph.D.(Scientific Founder)Rich Heyman, Ph.D.(Scientific Founder)Angie You, Ph.D.(Chief Executive Officer)

Co-investorsFRFrazier Life Sciences

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Z(Zhengbin (Bing) Yao(Executive Officer, Director)inBRBrent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCACatalio Capital Management, LPFOForesite CapitalGEGeneral CatalystHOHongShan Capital GroupLALAVLILilly Asia Ventures+2 more

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Co-investorsNENextech InvestRARA CapitalSRSR One Capital Management

BiotechHealthtechMedical DevicesWaltham, US

David F. Muller(Executive Officer, Director)inBJBrian J. Roberts(Executive Officer)inRJRhonda J. Bracey(Executive Officer)in

BoardJason Hong(Director)JDJeff Dykan(Director)inANAnthony Natale(Director)in

Co-investorsAPAPERTURE Venture PartnersLALAVLILilly Asia VenturesSCSCP Vitalife PartnersTHThird Point VenturesBOBorealis Ventures+1 more

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

ACAthena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDEDelos CapitalFOForesite CapitalININCE CapitalLOLongwood FundNENew Enterprise Associates (NEA)QUQuan Capital+3 more

Aviceda is a company that presents itself as backed by a range of investors, but the page provides no concrete details about its products or business area.

BiotechDigital HealthHealthtechMedical Devices

MAMohamed A. Genead(Chairman & CEO)inJNJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in

Co-investorsJEJeito CapitalLOLongitude CapitalDIDigitalis Ventures

Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.

BiotechHardwareMedical DevicesLebanon, US

TGTillman Gerngross(Director)EAErrik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsSVSV Health InvestorsBOBorealis VenturesMIMithril Capital ManagementPOPolaris PartnersSASands Capital VenturesSVSV Life Sciences

Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions.

BiotechHealthtechMedical Devices

Luba(Director of Pre-Clinical Development)

BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.

Biotech

JJJ. Jean Cui, Ph.D.(Scientific Founder, President and CEO)YPY. Peter Li, Ph.D., MBA(Cofounder and Executive Chairman)

Co-investorsVIVivo Capital

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.

BiotechHealthtech

VCVlad Coric(Chairman & Chief Executive Officer)in

Co-investorsAIAisling CapitalAPAPERTURE Venture PartnersCOConnecticut InnovationsOUOUP (Osage University Partners)HBHBM Healthcare Investments

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

TMTravis Murdoch, M.D.(Chief Executive Officer and Board Director)in

Co-investorsANAndreessen HorowitzFRFrazier Life Sciences

Biobeat develops a cuff-less, ambulatory blood pressure monitoring system built around a proprietary PPG sensor and a platform for tracking vital signs, aimed at helping physicians diagnose and manage hypertension.

Digital HealthHealthtechMedical Devices

ABArik B.(Founder)inABArik Ben Ishay(Founder & CEO)JMJohanan May(Founder, SVP & CTO)inISIsrael Sarussi(Founder, SVP R&D)inMGMichael Gioffredi(CCO)in

BoardRaymond W. Cohen(Chairman of the Board)

Co-investorsALAlly Bridge GroupRARaptor Group

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalSASamsara BioCapitalTCTCG CrossoverTHThird Rock VenturesVEvenBio PartnersVIVida Ventures

Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.

FemTechHealthtechHR TechSan Francisco, US

AAAsima Ahmad(Founder/CMO)inTSTammy Sun(Founder)inDavid Utley(Executive Officer, Director)

BoardSamir Kaul(Director)

Co-investorsALAll TurtlesAUAurumBABackstage CapitalCOCore Venture CapitalCRCRV (Charles River Ventures)DRDrive Capital+9 more

Cellipont Bioservices is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing and development services for advanced cell therapies.

Advanced ManufacturingBiotechHealthtechThe Woodlands, US

Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.

BiotechMedical DevicesBaltimore, US

Blake M. Paterson(Executive Officer, Director)Mariam Morris(Executive Officer)inRMRonald Marcus(Executive Officer)inUli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)inJames Vornov(Executive Officer)in

Co-investorsNENew Enterprise Associates (NEA)PEPETRICHOR SCION THERAPEUTICS

Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.

ConsumerCrypto & Web3FintechSocialNew York City, US

GNGray Newfield(Founder)inNNNoah Newfield(Founder)in

Co-investorsY Y Combinator46468 CapitalCACavalry VenturesFUFuel CapitalGRGradient VenturesKHKhosla Ventures+2 more

Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.

Developer Tools

Co-investorsBEBetaworksCACavalry VenturesGRGradient VenturesLOLOWERCARBONLOLowercarbon CapitalMOMotive Force+5 more

Charm.fi is a decentralized finance platform offering automated liquidity management vaults on Ethereum, letting users browse or create vaults for any token and build LP strategies to manage liquidity and earn yields.

Crypto & Web3Fintech

Co-investorsCOCoinbase VenturesCACavalry VenturesFUFuel CapitalGRGradient VenturesKHKhosla VenturesNENew Enterprise Associates (NEA)+1 more

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)

BoardRGRishi Gupta(Director)inNSNihal Sinha(Director)inMMMuzammil Mansuri(Director)inGary Glick(Director)in

Co-investorsF-F-Prime CapitalNENew Enterprise Associates (NEA)SRSR One Capital ManagementAXAxial VCKHKhosla VenturesNVNVentures

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMIMARK IWICKI(Executive Officer, Director)inMFMARTIN FREED(Executive Officer)in

BoardRHROB HOPFNER(Director)in

Co-investorsCACanaan PartnersSOSofinnova VenturesBABay City CapitalLOLongitude CapitalRARA Capital

BiotechBurlingame, US

Mark Rolfe(Executive Officer)LSLaura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)

BoardASAlfred Scheidegger(Director)inPTPeter Thompson(Director)inCarol Gallagher(Director)in

Co-investorsASAstellas Venture Management LLCNENew Enterprise Associates (NEA)NENextech Invest5A5AM VenturesCLClarus VenturesOSOsage University Partners+1 more

Convergent provides an AI simulation platform for enterprise training and skill development.

AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB

Co-investorsTETechstarsANAndreessen HorowitzRARA Capital

Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC).

BiotechHealthtech

PKPhilip Kantoff(Chief Executive Officer, Co-Founder)inNBNeil Bander(Senior Scientific Advisor, Co-Founder)ABAlex Brown(Chief Operating Officer)inADAndrew Davis(Chief Business and Strategy Officer)inELElizabeth L. Montgomery(Chief People Officer)inEMEric M. Sullivan(Chief Financial Officer)in

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

RARichard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)PTPeter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAVAvoro Capital AdvisorsFOForesite Capital

Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building.

BiotechHealthtechWuhan, CN

Co-investorsVIVivo CapitalLILilly Asia Ventures

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

GSGeorge Simeon(CEO)inGregory S. Curhan(CFO)GDGuy De La Rosa(CMO)in

Co-investorsADAdjuvant CapitalRARA CapitalSASanofi VenturesHBHBM Healthcare InvestmentsJAJanus Henderson InvestorsMEMedicxi

Cyrus provides a mobile app for personal cybersecurity and financial protection, offering account monitoring, dark web scanning, credit monitoring across three bureaus, VPN services, and fraud support for consumers.

ConsumerCybersecurityDigital Health

Co-investorsREResolute VenturesSPSPRINGROCK VENTURESRARainfall VenturesTHThe Fintech FundTRTrinity Ventures

Cyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning.

AI & Machine LearningBiotechDeep TechSeattle, US

Yifan Song(CSO)inDavid Baker(Co-founder)Javier Castellanos(Executive Officer, Director)inMark(President & EVP, Business Development)

BoardLNLucas Nivon(CEO)in

Co-investorsANAnzu PartnersARArgonautic VenturesISiSelect FundSPSPRINGROCK VENTURESSTStrawberry Creek VenturesTHThe W Fund+2 more

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

VVVictor Velculescu(Founder and Board Director)inPBPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSTSusan Tousi(Chief Executive Officer)in

Co-investorsAVAV8 VenturesFOForesite CapitalILIllumina VenturesINInitiate Venture PartnersMEMenlo VenturesOPOpen Field Capital+5 more

DIH is a healthcare technology company that develops rehabilitation and robotic therapy devices and software (including the Hocoma product line) for the medical and healthcare industry.

Digital HealthHardwareHealthtechMedical DevicesRoboticsZurich, CH

Jason(CEO and Chairman of the Board)

Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.

Cambridge, US

AJAnnalisa Jenkins(Executive Officer, Director)

BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)

Co-investorsF-F-Prime CapitalNENew Leaf Venture Partners

大米和小米 (DMHXM) operates a network of over 80 directly-run centers across more than 30 Chinese cities providing in-person early intervention and rehabilitation therapy for children with autism and developmental disorders, staffed by BCBA/BCaBA-certified therapists and experienced supervisors.

Digital HealthHealthtechWellness & FitnessShenzhen, CN

EC Healthcare provides medical aesthetic and healthcare services, including sales of medical aesthetic products, to consumers.